Terumo Expects Recall to Cut FY26 Operating Profit by JPY 41 Billion

• Terumo expects a JPY 41 billion operating profit hit in FY26 from its aortic-device recall and related asset-value risks.
• Global shipment suspensions since late October 2026 are expected to reduce revenue by JPY 8 billion.
• The voluntary recall followed testing that identified endotoxin levels exceeding specifications in thoracic and abdominal stent grafts.
• Blood and Cell Technologies forecasts FY27 revenue growth of at least 5%, supported by broader Reveos and Spectra Optia adoption.
• The business projects an adjusted operating profit increase exceeding JPY 5 billion, with a 20.4% adjusted operating profit margin.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Terumo Corporation published the original content used to generate this news brief on November 11, 2026, and is solely responsible for the information contained therein.